Aytu BioPharma, Inc.

NasdaqCM:AYTU Stock Report

Market Cap: US$15.6m

Aytu BioPharma Future Growth

Future criteria checks 3/6

Aytu BioPharma's revenue is forecast to decline at 12% per annum while its annual earnings are expected to grow at 96.6% per year. EPS is expected to grow by 98.8% per annum.

Key information

96.6%

Earnings growth rate

98.8%

EPS growth rate

Pharmaceuticals earnings growth22.8%
Revenue growth rate-12.0%
Future return on equityn/a
Analyst coverage

Low

Last updated15 Feb 2024

Recent future growth updates

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Recent updates

US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Feb 17
US$8.00 - That's What Analysts Think Aytu BioPharma, Inc. (NASDAQ:AYTU) Is Worth After These Results

Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Feb 16
Aytu BioPharma, Inc. (NASDAQ:AYTU) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Jan 23
Does Aytu BioPharma (NASDAQ:AYTU) Have A Healthy Balance Sheet?

Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Sep 29
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Share Price Boosted 59% But Its Business Prospects Need A Lift Too

Aytu stock falls amid suspending clinical programs to save costs

Oct 13

Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M

Sep 27

Aytu Biopharma adds fourth patent license for AR101 to treat rare genetic disorder

Sep 14

Aytu gets US patent for AR101/Enzastaurin for circulatory system disorders

Aug 16

Aytu BioPharma plunges on pricing $10M stock and warrants offering

Aug 09

Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

May 19
Earnings Release: Here's Why Analysts Cut Their Aytu BioPharma, Inc. (NASDAQ:AYTU) Price Target To US$8.00

Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Sep 11
Is Aytu Biopharma (NASDAQ:AYTU) Using Debt In A Risky Way?

Aytu BioPharma up 21% in afternoon trading

Jun 21

Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

May 15
Increases to Aytu Biopharma, Inc.'s (NASDAQ:AYTU) CEO Compensation Might Cool off for now

A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Feb 14
A Quick Analysis On Aytu BioScience's (NASDAQ:AYTU) CEO Compensation

Aytu BioScience: Time To Call In The Cavalry Of Value Catalysts

Dec 31

Aytu BioScience completes safety study in critically ill COVID-19 patients

Dec 28

Aytu Bio raises 'bought deal' offering to $25M

Dec 11

Aytu BioScience: The Barcode King Is Poised For An Epic Breakout

Nov 12

Earnings and Revenue Growth Forecasts

NasdaqCM:AYTU - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2026711N/AN/A1
6/30/2025773N/AN/A1
6/30/202484-12N/AN/A1
12/31/202398-1866N/A
9/30/2023102-2444N/A
6/30/2023107-17-5-5N/A
3/31/2023104-32-22-22N/A
12/31/2022106-77-28-28N/A
9/30/2022102-82-34-34N/A
6/30/202297-109-29-29N/A
3/31/202293-112-30-28N/A
12/31/202182-84-30-28N/A
9/30/202174-82-24-22N/A
6/30/202166-58-28-26N/A
3/31/202157-42-27-27N/A
12/31/202052-22-30-30N/A
9/30/202040-13-33-33N/A
6/30/202028-14-28-28N/A
3/31/202014-25-24-24N/A
12/31/20199-24-16-16N/A
9/30/20197-29-14-14N/A
6/30/20197-27-14-14N/A
3/31/20197-12-16-15N/A
12/31/20185-10-17-16N/A
9/30/20184-9-15-14N/A
6/30/20184-10-16-16N/A
3/31/20184-17-15-15N/A
12/31/20174-20-17-13N/A
9/30/20174-21N/A-13N/A
6/30/20173-23N/A-14N/A
3/31/20173-31N/A-13N/A
12/31/20163-33N/A-13N/A
9/30/20163-32N/A-14N/A
6/30/20163-28N/A-11N/A
3/31/20162-15N/A-10N/A
12/31/20151-10N/A-9N/A
9/30/20151-8N/A-7N/A
6/30/20150-8N/A-7N/A
3/31/20150-7N/A-7N/A
12/31/20140-7N/A-7N/A
6/30/20140-6N/A-6N/A
12/31/20130-4N/A-4N/A
6/30/20130-3N/A-3N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AYTU is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).

Earnings vs Market: AYTU is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AYTU is expected to become profitable in the next 3 years.

Revenue vs Market: AYTU's revenue is expected to decline over the next 3 years (-12% per year).

High Growth Revenue: AYTU's revenue is forecast to decline over the next 3 years (-12% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AYTU's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.